Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Receivables - Other: 2015-2023

Historic Receivables - Other for Spyre Therapeutics (SYRE) over the last 4 years, with Sep 2023 value amounting to $163,000.

  • Spyre Therapeutics' Receivables - Other was N/A to $163,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $163,000, marking a year-over-year change of. This contributed to the annual value of $375,000 for FY2022, which is 53.99% down from last year.
  • Spyre Therapeutics' Receivables - Other amounted to $163,000 in Q3 2023, which was down 90.10% from $1.6 million recorded in Q2 2023.
  • Spyre Therapeutics' Receivables - Other's 5-year high stood at $1.6 million during Q2 2023, with a 5-year trough of $163,000 in Q3 2023.
  • For the 3-year period, Spyre Therapeutics' Receivables - Other averaged around $723,500, with its median value being $595,000 (2021).
  • Data for Spyre Therapeutics' Receivables - Other shows a maximum YoY slumped of 67.39% (in 2023) over the last 5 years.
  • Over the past 3 years, Spyre Therapeutics' Receivables - Other (Quarterly) stood at $815,000 in 2021, then crashed by 53.99% to $375,000 in 2022, then tumbled by 67.39% to $163,000 in 2023.
  • Its last three reported values are $163,000 in Q3 2023, $1.6 million for Q2 2023, and $330,000 during Q1 2023.